Data / Drug companies / Rhodes Pharmaceuticals LLC
Rhodes Pharmaceuticals LLC: 68 products in the FDA NDC directory, labeler code 42858
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Rhodes Pharmaceuticals LLC (labeler code 42858) lists 68 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 68 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 30, 2026.
The request: Watch Rhodes Pharmaceuticals LLC (FDA labeler code 42858): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 42858
- Products in commercial distribution
- 68
- Packages
- 88
- Finished drugs by generic name
- 12
- Prescription products
- 68
- Over the counter products
- 0
- Controlled substance products
- Schedule II 54, Schedule III 9
- Flagged as original packager
- 59 of 59 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- November 23, 2009
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 45 | 66.2% |
| Authorized generics (NDA) | 16 | 23.5% |
| New drug applications (NDA) | 7 | 10.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 68 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Morphine sulfate | 8 | 31 |
| Hydromorphone hydrochloride | 8 | 20 |
| Lisdexamfetamine dimesylate | 7 | 16 |
| Methylphenidate hydrochloride | 7 | 39 |
| Buprenorphine | 7 | 24 |
| Oxycodone hydrochloride | 5 | 36 |
| Oxycodone and acetaminophen | 3 | 32 |
| Hydrocodone bitartrate and acetaminophen | 3 | 37 |
| Fenofibrate | 2 | 56 |
| Buprenorphine and naloxone | 2 | 22 |
| Maraviroc | 2 | 9 |
| Scopolamine | 1 | 12 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 28 | 41.2% |
| Capsule, extended release | 13 | 19.1% |
| Tablet, film coated, extended release | 8 | 11.8% |
| Capsule | 7 | 10.3% |
| Patch | 5 | 7.4% |
| Tablet, film coated | 4 | 5.9% |
| Solution | 2 | 2.9% |
| Patch, extended release | 1 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Central Nervous System Stimulant | 27 |
| Opioid Agonist | 27 |
| Partial Opioid Agonist | 9 |
| Peroxisome Proliferator Receptor alpha Agonist | 2 |
| Opioid Antagonist | 2 |
| CCR5 Co-receptor Antagonist | 2 |
| Anticholinergic | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Maraviroc | 42858-247 | Tablet, film coated | Generic drugs (ANDA) | September 30, 2026 |
| Maraviroc | 42858-246 | Tablet, film coated | Generic drugs (ANDA) | September 30, 2026 |
| Scopolamine | 42858-150 | Patch, extended release | Generic drugs (ANDA) | November 1, 2024 |
| Lisdexamfetamine dimesylate | 42858-167 | Capsule | Generic drugs (ANDA) | January 30, 2024 |
| Lisdexamfetamine dimesylate | 42858-166 | Capsule | Generic drugs (ANDA) | January 30, 2024 |
| Lisdexamfetamine dimesylate | 42858-165 | Capsule | Generic drugs (ANDA) | January 30, 2024 |
| Lisdexamfetamine dimesylate | 42858-164 | Capsule | Generic drugs (ANDA) | January 30, 2024 |
| Lisdexamfetamine dimesylate | 42858-163 | Capsule | Generic drugs (ANDA) | January 30, 2024 |
| Lisdexamfetamine dimesylate | 42858-162 | Capsule | Generic drugs (ANDA) | January 30, 2024 |
| Lisdexamfetamine dimesylate | 42858-161 | Capsule | Generic drugs (ANDA) | January 30, 2024 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate | 42858-727 | Tablet | Generic drugs (ANDA) | September 9, 2021 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate | 42858-726 | Tablet | Generic drugs (ANDA) | September 9, 2021 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate | 42858-725 | Tablet | Generic drugs (ANDA) | September 9, 2021 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate | 42858-724 | Tablet | Generic drugs (ANDA) | September 9, 2021 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate | 42858-723 | Tablet | Generic drugs (ANDA) | September 9, 2021 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate | 42858-722 | Tablet | Generic drugs (ANDA) | September 9, 2021 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate | 42858-721 | Tablet | Generic drugs (ANDA) | September 9, 2021 |
| Buprenorphine and Naloxone | 42858-602 | Tablet | Generic drugs (ANDA) | April 13, 2020 |
| Buprenorphine and Naloxone | 42858-601 | Tablet | Generic drugs (ANDA) | April 13, 2020 |
| Methylphenidate Hydrochloride | 42858-081 | Capsule, extended release | Authorized generics (NDA) | April 1, 2020 |
| Methylphenidate Hydrochloride | 42858-080 | Capsule, extended release | Authorized generics (NDA) | April 1, 2020 |
| Methylphenidate Hydrochloride | 42858-079 | Capsule, extended release | Authorized generics (NDA) | April 1, 2020 |
| Methylphenidate Hydrochloride | 42858-078 | Capsule, extended release | Authorized generics (NDA) | April 1, 2020 |
| Methylphenidate Hydrochloride | 42858-077 | Capsule, extended release | Authorized generics (NDA) | April 1, 2020 |
| Methylphenidate Hydrochloride | 42858-076 | Capsule, extended release | Authorized generics (NDA) | April 1, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.